VPAG

Market Access

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.

News

The UK has awarded nearly £50m in funding for equipment to help the NHS carry out commercial clinical trials, with a focus on primary care capacity.

Market Access

Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.

News

The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."

Market Access

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.